Philip Morris
860000 World Health Assembly 860505 - 860516 Background / General Principles
Fields
- Master ID
- 2501442800/3320
Related Documents:- 2501442800-2806 Report of the Surgeon General's Advisory Committee on the Health Consequences of Using Smokeless Tobacco
- 2501442807-2808 the Thirty-Ninth World Health Assembly Geneva, 860505 - 860516
- 2501442809-2811 Seventy-Seventh Session Agenda Item 15 Tobacco or Health
- 2501442812-2817 Economic Data for Tobacco in Selected Countries
- 2501442818-2827 Comments on the Proposed Who Resolution Eb77/22 Add. 2 Dated 860111
- 2501442828-2829 Report on World Health Organization's Work Related to the Tobacco Industry
- 2501442830-2897 the World Health Organization (Who): Its Work Related to the Activities of the International Tobacco Industry
- 2501442898-2901 Zimbabwe and the World Health Assembly
- 2501442902-2905 Critique of Who Report Eb77/22 Add 1 Entitled 'the Adverse Health Effects of Tobacco Use'
- 2501442906-2907 Action Alert 860000 World Health Assembly
- 2501442913 Healthy Buildings 880000
- 2501442914-2916
- 2501442917-2925 Healthy Buildings 88
- 2501442926-2927 Cib Healthy Buildings 880000
- 2501442928-2930 A Guide to Future Healthy Buildings
- 2501442931-2940 Why Does Air Make People Sick?
- 2501442941
- 2501442942-2944 Energy Conservation Programs Have Made Matters Worse
- 2501442945-2947 More Fresh Air Makes for Healthier Buildings
- 2501442948-2952 Clear Indoor Air: A Trade Union Perspective
- 2501442953-2954
- 2501442955-2957
- 2501442958-2959
- 2501442960-2961
- 2501442962-2963
- 2501442965-3067 Cigarette Smoking and Cancer: A Scientific Perspective
- 2501443068-3119 Cigarette Smoking and Heart Disease
- 2501443120-3256 Smoking and Health 640000 - 790000 the Continuing Controversy
- 2501443257-3286 Chronic Obstructive Pulmonary Disease (Copd)
- 2501443288-3301 Cigarette Smoking and Chronic Obstructive Lung Diseases: the Major Gaps in Knowledge
- 2501443302
- 2501443303-3320 Tobacco Issues Claims Vs. Facts
- Type
- REPT, REPORT, OTHER
- Area
- BRUSSELS S&H/EU ARCHIVE
- Site
- E96
- Characteristic
- MARG, MARGINALIA
- Named Organization
- 1984 World Health Assembly
- 1986 World Health Assembly
- 21st World Health Assembly
- Executive Board
- Ifpma
- Pharmaceutical Mfg Assn
- Program Comm
- Un, United Nations
- Who Nairobi Conference of Experts on the
- Who, World Health Org
- World Health Assembly
- 1986 World Health Assembly
- Litigation
- Stmn/Produced
- Attachment
- 2501442906/2501442912
- Request
- Stmn/R1-004
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- gyh22e00
Document Images
7 8-3
1986 WORLD HEALTH ASSEMBLY
May 5-16, 1986
Background/General Principles
Background
The Thirty-ninth World Health Assembly provisional agenda contains three items
of potential concern to the international corporate community. These include:
° Item 21 - Progress/Evaluation of Report on Implementation of the
WHO Code on the Marketing of Breast Milk Substitutes.
° Item 22 - Resolution on "Tobacco or Health" and proposed WHO
action pro,gram on tobacco.
° Item 25 - Rational Use of Drugs (Follow-up to November 1985
WHO Nairobi Conference of Experts on the Rational Use of Drugs).
A. Re ort on Im lementation of WHO Code on the Marketin of
Breast i u stitutes
This Code, adopted by the WHO in 1981, was in the form of recommendations to
national governments, to serve as the basis for possible national legislation
on the marketing of breast milk substitutes. Among other provisions the Code
prohibits point of sale advertising and advertising to the general public, and
restricts the promotion of infant formula by health care professionals.
Industry associations and research groups raised several concerns with the
Code, among them its undocumented assumptions on the health and social impacts
of infant formula, definitional ambiguities, and possible spill-over into
other product areas.
The Code called for a review of implementation of its provisions in three
years. In a 1984 report the WHO noted that some 130 governments had taken
steps to implement the Code. The WHO then voted to review progress on the
Code every two years.
The May 1986 WHA will be the occasion for the next of these progress reports.
This report raises concerns in two respects.
First, the 1984 WHA passed a resolution which asks governments to examine the
promotion and use of foods unsuitable for infant and young child feeding, and
calls for a report to the 1986 WHA. This raises the possibility that there
may be attempts to expand the 1981 Code into the area of advertising of food
in general to children. The report has not yet been circulated.
N
CJ7
0
~
~
~
N
o
0
~

Second, the WHO has been examining the interpretation of Article 6 of the
Co e, on supplies of low-priced breast milk substitutes for "infants who have
to be fed on breast milk substitutes." Questions on this and other aspects of
the Code raise the specter of reopening the divisive debate on the issue, with
some likely to call for broadening the scope of the Code to subjects beyond
breast milk substitutes as defined in the 1981 Code. This would run counter
to the intent of the drafters not to expand the Code.
Action: National committees should contact their governments and urge that
ey take the following principles into account when preparing for discussion
of this item at the WHA:
° In most cases breast milk is the chosen method of feeding
infants.
° Malnutrition, hunger and famine continue as major problems,
especially in developing countries.
° Processed foods offer a wide range of wholesome nutrients
that have an important role in the diets of infants and
young children as well as adults.
° Efforts to restrict the availability of these foods - either
through direct prohibitions or through indirect marketing
restrictions targeted at the same objective - are inimical to
the interests of consumers in developing countries and their
freedom of choice.
° Since marketing practices differ greatly from country to country,
these should be s ep cific to needs, cultures, and mores.
° Extension of the International Code of Marketing of Breast Milk
Substitutes should be resisted since it is an encroachment into
the national authority of member states over the legitimate
marketing of foodstuffs.
B. Resolution on "Tobacco or Health"/WHO Action Program on Tobacco
Since the early 1970s, the WHO has been conducting an anti-smoking campaign,
which has received minimum financial support. Single-issue organizations have
taken this fact as an opportunity to provide their time, money and effort in
return for WHO worldwide influence. In 1986, prompted by pressure from such
groups, the WHO Executive Board considered a report entitled "Tobacco or
Health," and adopted a resolution which encourages developing country
governments to adopt strong anti-tobacco legislation.
The tone of the report is clearly set out by the Program Committee which
openly establishes an adversarial relationship between itself and industry
which it characterizes as "...the battle between health and commercial
interests..."
It is acknowledged that WHO has a useful role to play in educating the public
on the alleged health effects of tobacco consumption, based on scientific
evidence. However, the Report approaches the smoking and health issue not
from a scientific viewpoint but rather represents one more example of the
"politicization" of an organization supposedly devoted to health and objective
science.
N
6n
0
~
.~
~
N
~
0
~
-2-

The resolution includes a provision which "deplores all direct and indirect
practices the aim of which is to promote the use of tobacco." In effect, it
calls for government intervention into the private sector and calls for
support by other U.N. organizations in WHO's anti-smoking efforts.
The "Tobacco or Health" resolution advocates direct and far-reaching inter-
vention in trade and economic issues. This resolution raises many concerns.
° It supports and encourages total bans of advertising, which
deny both the freedom to advertise legal products and also the
right of consumers to be informed about those products.
° It seeks the eventual elimination of tobacco leaf growing
and trade along with all sectors of the tobacco industry
worldwide.
It has been reported that the WHO Director General will submit a program of
action implementing the resolution to the 1986 WHA, the details of which will
not be available until mid-April.
Action: National committees should contact their governments and urge that
t~iey take the following principles into account when preparing for discussions
of this item at the WHA.
° The aim to eliminate tobacco is a direct attack on the
entire industry - including cultivation, processing,
manufacture and marketing of tobacco products of all kinds.
As such it would result in major loss of revenue and exchange
earnings in many countries. This is another instance of how WHO
is expanding its scope beyond areas relating strictly to health
and into areas affecting trade, economics and commerce.
° The call for advertising bans ignores empirical evidence in those
countries where bans are in force. Bans have been found to have
had no significant effect on overall consumption levels, but ,~
have rather removed a major means of market competition and com- a
munication with consumers. ~
.~
C. Rational Use of Drugs ^'
~
~
At its 1984 World Health Assembly, WHO adopted a resolution calling for a °
meeting of experts (including governments, the pharmaceutical industry,
patients, and consumer organizations) in 1985 to discuss means of ensuring the
rational use of drugs (through improved knowledge and information flow) and
the role of marketing practices.
That meeting was held November 25-29, 1985. Those experts agreed that WHO
should not serve as supranational regulator, but should leave action to
national governments as appropriate to their socio-economic health and legal
systems. They then recommended that experts groups be set up to deal with six
areas:
-3-

° national drug policies
° registration and labelling
° WHO drug certification scheme
° information
° training
° norms for ethical promotion of drugs
In February, the WHO released a "Revised Drug Strategy," incorporating the
conclusions of the Nairobi meeting, for consideration at the WHA. The strate-
gy notes that the WHO will: foster fulfillment by each concerned party of its
responsibilities; support governments in formulating and implementing national
drug policies; expand normative functions (including extension of the WHO drug
certification scheme, guidelines for drug regulatory authorities, guidelines
for formulating national drug legislation, and update of ethical criteria for
drug advertising adopted by the 21st WHA), intensify information dissemina-
tion; provide education/training of health care personnel; and promote collab-
orative research.
An area of major concern to industry is that relating to norms for ethical
promotion of drugs (also referred to as the "update of ethical criteria for
drug advertising"). This is seen as possibly opening the door for preparation
of a code on the marketing of pharmaceuticals which would represent an
intervention into national drug policy-making.
Action: National committees should work with local chapters of pharmaceutical
manufacturers associations, or the IFPMA, in contacting governments regarding
the WHA discussion.
General principles which could be stressed include the following:
° It is essential to evaluate the availability, promotion and
use of drugs in the Third World in the context of each country
and not according to the standards of the more developed health-
care systems. Adapting the products of these systems to the
circumstances found in the Third World - and meeting Third World
health problems head on - is a continuing challenge that the
pharmaceutical industry is committed to meeting.
° National and regional conditions and legislation vary so much that
a highly detailed, universally applicable code would be impractical.
° IFPMA has in existence a widely publicized Code and has encouraged
health-care authorities, health-care professionals and consumer
groups to make use of its complaint procedure.
° For years, pharmaceutical companies have been working to improve
the health and lives of people in developing countries. These
activities include investing large amounts of capital, trans-
ferring technology, training and employing thousands of local
workers, setting up research centers, training health-care
workers, and improving health-care services.
t
,
-4-

° While allowing that progress in pharmaceuticals has been made, in-
dustry critics claim it has come to an excessive cost resulting in
too many drugs and high prices. Their solution is to restrict the
number of drugs available on the market. In fact, restricted drug
lists would remove from industry the incentive and means to conduct
future R&D.
Conclusion:
All of the above contain a common element - attempts to restrict the
advertising and promotion of products in accordance with national laws. In
communicating with their governments, national committees should place great
emphasis on the need to maintain the free flow of product information which
enables consumers to make free and informed choices.
